Alexion Pharmaceuticals Inc. last week laid out its plans for keeping up the momentum that has resulted in a doubling of market cap in the past year, from $4.1 billion on Feb. 12, 2010, to $8.2 billion on Friday.
The path forward lies in expansion of its Soliris eculizumab franchise and acquisitions of assets that fit with its focus on rare and severe disorders. Two of these - the acquisition of Taligen Therapeutics Inc. and a program from Orphatec Pharmaceuticals GmbH - were announced within the last two weeks.
Alexion also is building a translational organization to advance its early stage assets.
Alexion markets Soliris - its only approved product - in 35 countries for paroxysmal nocturnal hemoglobinuria (PNH). About 8,000-10,000 patients in North America and Western Europe have PNH, which is an acquired